Skip to Content

Neuromuscular Disorders Clinical Trials

RESTORE: A Clinical Study of Patients with Symptomatic Neurogenic Orthostatic Hypotension to Assess Sustained Effects of Droxidopa Therapy

Aims: The purpose of this study is to evaluate the durability, effectiveness and safety of the study drug, droxidopa, in those with neurogenic orthostatic hypotension (NOH). Droxidopa (NORTHERA) has been approved in the United States for treatment of NOH. However, effectiveness beyond 2 weeks has not been demonstrated. This study is placebo-controlled to assess the benefits beyond 2 weeks and is therefore investigational. Total study participation can be up to 36 weeks.
Principal Investigator: Alexandru Barboi, MD
NorthShore Project Number: EH18-106
Contact: Please call 847.503.4334 with questions regarding the study
Open to Enrollment: Yes

An Open-Label, Expanded Access Protocol for Firdapse® (Amifampridine Phosphate; 3,4-Diaminopyridine Phosphate) Treatment in Patients with Lambert-Eaton Myasthenic Syndrome (LEMS), Congenital Myasthenic Syndrome (CMS) and Downbeat Nystagmus
Aims: The primary objective of the study is to provide patients with LEMS/CMS/downbeat nystagmus access to amifampridine phosphate therapy until the product becomes commercially available. The secondary objective of the study is to assess the long-term safety of amifampridine.
Principal Investigator: Alexandru Barboi, MD
NorthShore Project Number: EH16-121
Contact: Please call 847.570.4046 with questions regarding the study
Open to Enrollment: Yes

Rapid Number Naming Performance in Myasthenia Gravis (MG) using the King-Devick (K-D) Test
Aims:
The purpose of this study is to investigate the change in K-D rapid eye movement performance test with initiation or change in MG treatment and clinical improvement.  This study also aims to define the relation of K-D test performance to standard clinical measures of MG in both visual and MG-specific quality of life scores.
Principal Investigator:
John Pula, MD
NorthShore Project Number:
EH18-010
Contact:
Please call 224.251.2020 with questions regarding the study.
Open to Enrollment:
Yes